• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Valeant Pharmaceuticals to acquire Solta Medical

Valeant Pharmaceuticals to acquire Solta Medical

December 16, 2013
CenterWatch Staff

Valeant Pharmaceuticals International will acquire all outstanding common stock of Solta Medical for $2.92 per share in cash, for a transaction value of approximately $250 million. The transaction is expected to close in the first quarter of 2014.

Solta designs, develops, manufactures and markets energy-based medical device systems for aesthetic applications. Solta's products include the Thermage CPT system that provides non-invasive treatment options using radiofrequency energy for skin tightening, the Fraxel repair system for use in dermatological procedures requiring ablation, coagulation and resurfacing of soft tissue, the Clear + Brilliant system to improve skin texture and help prevent the signs of aging skin and the Liposonix system that destroys unwanted fat cells resulting in waist circumference reduction.  Solta had total revenue of approximately $145 million in 2012. 

"Our board of directors has determined that this all-cash offer is in the best interest of our stockholders," said Mark Sieczkarek, chairman of the board and Interim CEO of Solta Medical. "Valeant has a proven track record of successfully integrating a number of acquisitions into their portfolio and has established a presence in the aesthetics market. The addition of Solta's brands and global sales organization creates a very compelling platform for future growth in the medical aesthetic segment."

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing